XTL Biopharmaceutica (Israel) Probability of Target Price Finishing Over Current Price

XTLB -- Israel Stock  

ILS 8.20  0.50  5.75%

XTL Biopharmaceutica probability of target price tool provides mechanism to make assumptions about upside and downside potential of XTL Biopharmaceuticals Ltd performance during a given time horizon utilizing its historical volatility. Please specify XTL Biopharmaceutica time horizon, a valid symbol (red box) and a target price (blue box) you would like XTL Biopharmaceutica odds to be computed. See also Your Current Watchlist.
Horizon     30 Days    Login   to change
Symbol:
Refresh Odds

XTL Biopharmaceutica Target Price Odds to finish over

Current PriceHorizonTarget PriceOdds to move above current price in 30 days
 8.20 30 days 8.20  ABOUT 61.14%
Based on normal probability distribution, the odds of XTL Biopharmaceutica to move above current price in 30 days from now is about 61.14% (This XTL Biopharmaceuticals Ltd probability density function shows the probability of XTL Biopharmaceutica Stock to fall within a particular range of prices over 30 days) .
Assuming 30 trading days horizon, XTL Biopharmaceutica has beta of 0.288 . This means as returns on market go up, XTL Biopharmaceutica average returns are expected to increase less than the benchmark. However during bear market, the loss on holding XTL Biopharmaceuticals Ltd will be expected to be much smaller as well. Additionally XTL Biopharmaceuticals Ltd has an alpha of 0.9644 implying that it can potentially generate 0.9644% excess return over DOW after adjusting for the inherited market risk (beta).
 XTL Biopharmaceutica Price Density 
      Price 
α
Alpha over DOW
=0.96
β
Beta against DOW=0.29
σ
Overall volatility
=1.28
Ir
Information ratio =0.14

XTL Biopharmaceutica Alerts

XTL Biopharmaceutica Alerts and Suggestions

XTL Biopharmaceutica is not yet fully synchronised with the market data
XTL Biopharmaceutica has very high historical volatility over the last 30 days
XTL Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years
XTL BIOPHARMAC has accumulated about 5.41M in cash with (1.12M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Latest headline from finreviewer.com: Css Continues to Hold Position in Discovery Merck Co. Holder Doheny Asset Management Has Increased Holding - The FinReviewer

Price Density Drivers

XTL Biopharmaceutica Health Indicators

Float Shares224.08M
Average Daily Volume Last 10 Day1.39M
Average Daily Volume In Three Month2.97M
See also Your Current Watchlist. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
Search macroaxis.com